Kangshun Zhu
机构：Zhejiang Chinese Medical University, Guangdong University of Technology, Second Affiliated Hospital of Guangzhou Medical University, Society of Interventional Radiology, Precision for Medicine (United States), Guangdong Provincial Center for Disease Control and Prevention, GCI Science & Technology (China), Guangzhou Medical University · ORCID：0000-0001-5142-010X
发表论文 168 篇 · 总被引 5853 次 · h-index 37
代表论文
- Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions (2024 · Signal Transduction and Targeted Therapy · 被引 642)
- Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study (2024 · EClinicalMedicine · 被引 157)
- China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) (2025 · Liver Cancer · 被引 51)
- Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study (2024 · Liver International · 被引 29)
- Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study (2024 · International Journal of Surgery · 被引 23)
- Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study (2024 · Liver Cancer · 被引 14)